Nektar Therapeutics
201 Industrial Road
San Carlos, California 94070
Sender Contact Information
P: (650) 620-5990
F: (650) 620-5360
January 14, 2009
VIA FACSIMILE AND U.S. MAIL
Securities and Exchange Commission
Division of Corporate Finance
Washington, D.C. 20549
Attention: Nandini Acharya, Esq.
Re: | Nektar Therapeutics. -- Form 10-K for the Year Ended December 31, 2007 (File No. 000-24006) |
Dear Ms. Acharya:
This request is in relation to the letter dated December 10, 2008 (the “Comment Letter”), including comments from the staff of the Securities and Exchange Commission to the Form 10-K for the year ended December 31, 2007 (File No. 000-24006) filed by Nektar Therapeutics, a Delaware corporation, on February 29, 2008.
We respectfully request an extension to January 23, 2009 to provide a response to the Comment Letter.
Please do not hesitate to call the undersigned at (650) 620-5990 or Jennifer A. DePalma, Esq. of O’Melveny & Myers LLP, legal counsel to Nektar Therapeutics, at (650) 473-2670, regarding this matter.
Sincerely, |
/s/ Gil M. Labrucherie |
Gil M. Labrucherie |
Senior Vice President, General Counsel & Secretary of Nektar Therapeutics |
cc: | Howard W. Robin, President and Chief Executive Officer of Nektar Therapeutics |
Sam Zucker, Esq., O’Melveny & Myers LLP | |
Jennifer A. DePalma, Esq., O’Melveny & Myers LLP |